Gateway® LR Clonase™ Enzyme Mix

Cat. No. 11791-019  Size: 20 reactions
Cat. No. 11791-043  Size: 100 reactions
Store at -80°C

Gateway® Technology
Gateway® is a universal cloning technology based on the site-specific recombination properties of bacteriophage lambda (1). The Gateway® Technology provides a rapid and highly efficient way to move DNA sequences into multiple vector systems for functional analysis and protein expression, and can be schematically represented as follows:

\[
\text{attL} \times \text{attR} \times \text{attP} \text{ reaction is mediated by Gateway® BP Clonase™ enzyme mix; the attL} \times \text{attR reaction is mediated by Gateway® LR Clonase™ enzyme mix. ccdB is the F plasmid-encoded gene that inhibits growth of } E. coli \text{ (2,3) and “gene” represents any DNA segment of interest (e.g. PCR product, cDNA, genomic DNA).}
\]

Description
Gateway® LR Clonase™ enzyme mix is a proprietary enzyme formulation containing the bacteriophage lambda recombination proteins Integrase (Int) and Excisionase (Xis), and the \(E. coli\)-encoded protein Integration Host Factor (IHF) (1). Gateway® LR Clonase™ enzyme mix promotes \textit{in vitro} recombination between an entry clone (\text{attL}-flanked “gene”) and any number of \text{attR}-containing destination vectors to generate \text{attB}-containing expression clones. “Genes” present in expression clones can be transferred back into an entry vector by mixing with an \text{attP} Vector (e.g., pDONR™221) and adding Gateway® BP Clonase™ enzyme mix.

Components Supplied

<table>
<thead>
<tr>
<th></th>
<th>20 rxns</th>
<th>100 rxns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gateway® LR Clonase™ Enzyme Mix</td>
<td>80 µl</td>
<td>400 µl</td>
</tr>
<tr>
<td>5X LR Clonase™ Reaction Buffer</td>
<td>200 µl</td>
<td>1 ml</td>
</tr>
<tr>
<td>2 µg/µl Proteinase K Solution</td>
<td>40 µl</td>
<td>200 µl</td>
</tr>
<tr>
<td>50 ng/µl pENTR™-gus Positive Control</td>
<td>20 µl</td>
<td>20 µl</td>
</tr>
</tbody>
</table>

This product is distributed for laboratory research only. CAUTION: Not for diagnostic use. The safety and efficacy of this product in diagnostic or other clinical uses has not been established.

For technical questions about this product, call the Invitrogen Tech-Line™ U.S.A. 800 955 6280
General Recommendations and Guidelines

- pENTR™-gus is provided for use as a positive control in the LR reaction, and is an entry clone containing the *Arabidopsis thaliana* β-glucuronidase (gus) gene (4). 1 µg of supercoiled pENTR™-gus plasmid is supplied in TE Buffer, pH 8.0 at a concentration of 50 ng/µl. Note: See our Web site (www.invitrogen.com) for a map and the sequence of pENTR™-gus.

- We recommend using plasmid DNA purified with the S.N.A.P.™ MiniPrep Kit (Catalog no. K1900-01). Mini-prep (alkaline lysis) DNA preparations are adequate for Gateway® cloning reactions; however, in general, such DNA cannot be quantitated by UV absorbance due to contaminating RNA and nucleotides. Estimate concentrations by gel electrophoresis in comparison with standard DNA, i.e., DNA Mass Ladder (Cat. Nos. 10068-013 or 10496-016).

- For LR reactions, the most efficient substrates are supercoiled attL-containing entry vectors and supercoiled attR-containing destination vectors. For large (>10 kb) entry clones or destination vectors, linearizing the entry clone or destination vector may increase the efficiency by up to 2-fold.

- To increase the number of colonies containing the desired expression clone, increase the incubation time from the recommended 1 hour to 2 hours or overnight. Longer incubations are recommended for plasmids ≥10 kb to increase the yield of colonies.

- We recommend using 100-300 ng entry clone per 20 µl reaction. Highest colony yields are typically obtained using 300 ng entry clone and 300 ng destination vector. Do not use >300 ng entry clone as you may obtain colonies containing multiple DNA molecules (often with an associated “small colony” phenotype). Using <100 ng entry clone will generate fewer colonies.
Procedures

LR Reaction
Use the following procedure to perform an LR recombination reaction. For a positive control, use 100 ng (2 µl) of pENTR™-gus.

1. Add the following components to a 1.5 ml microcentrifuge tube at room temperature and mix:
   - Entry clone (100-300 ng) 1-10 µl
   - Destination vector (150 ng/µl) 2 µl
   - 5X LR Clonase™ Reaction Buffer 4 µl
   - TE buffer, pH 8.0 to 16 µl
2. Remove LR Clonase™ enzyme mix from -80°C and thaw on ice for about 2 minutes. Vortex the LR Clonase™ enzyme mix briefly twice (2 seconds each time).
3. To each sample (Step 1, above), add 4 µl of LR Clonase™ enzyme mix to the reaction and mix well by vortexing briefly twice. Microcentrifuge briefly.
4. Return LR Clonase™ enzyme mix to -80°C storage immediately after use.
5. Incubate reactions at 25°C for 60 minutes.
6. Add 2 µl of the Proteinase K solution to each sample to terminate the reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.

Transformation

1. Transform 1 µl of each LR reaction into 50 µl of Library Efficiency™ DH5α™ Competent Cells (Cat. No. 18263-012). Incubate on ice for 30 minutes. Heat-shock cells by incubating at 42°C for 30 seconds. Add 450 µl of S.O.C. Medium and incubate at 37°C for 1 hour with shaking. Plate 20 µl and 100 µl of each transformation onto selective plates.
   - Note: Any competent cells with a transformation efficiency of >1.0 × 10^8 transformants/µg may be used.
2. Transform 1 µl of pUC19 DNA (10 ng/ml) into 50 µl of Library Efficiency™ DH5α™ Competent Cells as described above. Plate 20 µl and 100 µl on LB plates containing 100 µg/ml ampicillin.

Expected Results
An efficient LR recombination reaction will produce >5000 colonies if the entire transformation is plated.
Quality Control
LR Clonase™ enzyme mix is functionally tested in a 1 hour recombination reaction followed by a transformation assay.

References

Limited Use Label License No. 19: Gateway® Cloning Products
The Gateway® Cloning Technology products and their use are the subject of one or more of U.S. Patent Nos. 5,888,752, 6,443,527, 6,171,861, 6,270,969, and 6,277,608 and/or other pending U.S. and foreign patent applications owned by Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). No license is conveyed under the foregoing patents to use this product with any recombination sites other than those purchased from Invitrogen Corporation or its authorized distributor. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product produced in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1680 Fanaday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Limited Use Label License No. 23: GUS Control Vector
The GUS positive control vector in these products is claimed in patents and patent applications (See U.S. Patent No. 5,599,670 and Great Britain Patent No. 2,197,653) licensed to Invitrogen by Cambia Biosystems, L.L.C. (‘CBL’). Use of the GUS gene is restricted to use as a positive control. Any other use may require a license from CBL.

©2003 Invitrogen Corporation. All rights reserved.